Vertiv Holdings (NYSE:VRT) on Monday was rated Outperform in new research coverage by analysts at investment firm William ...

Lenz Therapeutics has earned the FDA’s go-ahead for its aceclidine eye drop to crack the large presbyopia market, where past ...

Jed Dorsheimer, William Blair analyst, joins 'The Exchange' to discuss Tesla's chip deal with Samsung and what it means for ...

PTC Therapeutics secures FDA approval for Sephience in PKU, launching August with analysts projecting strong revenue and ...

William Blair is the premier global boutique with expertise in investment banking, investment management, and private wealth management. We provide advisory services, strategies, and solutions to ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) reported upbeat second-quarter earnings and 2025 guidance on Thursday. The company ...

William Blair is increasingly known for its prominence in the asset management business, with a global footprint of more than $81.9 billion¹ in client assets as of December 31, 2018.

In addition, The Allstate Corporation (NYSE:ALL) is taking advantage of a far better auto loss environment and employing ...

William Blair cheers Tesla-Samsung chip deal but keeps TSLA at Hold, citing auto margin woes and valuation concerns.

Palo Alto Networks, Inc. (NASDAQ:PANW) is one of the best long term low volatility stocks to buy now. On July 16, William ...

William Blair wouldn’t immediately say how many total bankers it has currently, but that figure was 370 worldwide as of April 2019, so the reduction relative to that past banker headcount would ...